SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards following news of a planned bond sale to fund AI investments, sparking concerns about increased spending and potential impact on shareholder value. The community is debating whether the dip presents a buying opportunity, considering the company's fundamentals and long-term growth potential amid the AI push. Some investors are drawing comparisons to past overspending concerns while others see it as a strategic move for future growth.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's stock is trending as investors anticipate upcoming earnings, with the community closely watching key metrics like user growth and advertising revenue. Bullish sentiment is fueled by analysts setting higher price targets and highlighting potential from AI and data licensing deals. Short interest is also a key factor being watched.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies behind the OG meme, fueled by a desire to reclaim internet culture. Discussions center on achieving the #1 spot and bringing back the spirit of the 2021 meme era. The community emphasizes belief, teamwork, and rejecting traditional financial analysis in favor of cultural relevance.

Cambium Networks Corp. is a holding company, which engages in the provision of wireless broadband networking infrastructure solutions for network operators. Its products include point-to-point, enterprise Wi-Fi and switching, CCTV, software, and point-to multipoint. The company was founded in 2011 and is headquartered in Hoffman Estates, IL.

Cambium Networks Corp

CMBM is trending due to excitement around its integration with Starlink, with retail traders discussing a potential short squeeze and high trading volume. Community members are debating resistance levels and potential price targets, while also weighing the company's fundamentals and potential for further gains. The stock's volatile price action and significant overnight gains have fueled speculation about its short-term trajectory.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle ($CMG) is trending due to a significant drop following a lowered sales outlook, sparking discussions about consumer spending and the company's value proposition. Community members are debating whether the dip is a buying opportunity or a sign of deeper issues with the brand, citing concerns about pricing, portion sizes, and competition in the fast-casual dining sector.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors anticipate earnings, with community members pointing to the stock's recent strength and potential AI-driven growth. Discussions include Google's partnership with Reliance Jio in India and its increased capital expenditure outlook, with some expecting the stock to test the $300 level. Bullish sentiment is fueled by positive analyst ratings and expectations of a strong quarter.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as it approaches earnings, fueled by optimism around its AI and cloud services. The community is actively discussing the stock's impressive run and debating whether it's overbought, while also noting Google's expansion into new sectors like nuclear energy.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific ($CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV), with many in the community expressing concerns that the deal undervalues $CORZ, particularly given its AI infrastructure potential. Some investors believe that rejecting the deal could lead to a higher valuation for $CORZ as a standalone entity or attract a better offer, while others worry about the company's future prospects without the merger.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending due to raised FY25 EBITDA guidance, sparking optimism about the company's future profitability. The community is discussing the potential for a significant stock re-rating and a short squeeze, with some highlighting the low P/E ratio relative to the broader market. Discussions also involve potential catalysts like government appropriations and debt refinancing.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC Corp. is experiencing a significant drop, driven by a dividend cut and lowered full-year earnings expectations, prompting community concern about potential debt issues and bankruptcy. Despite the downturn, some investors view the stock as oversold, anticipating a turnaround as the company focuses on debt reduction. Community members are actively discussing entry points, potential rebound levels, and whether the steep decline is an overreaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.</li><li>The company said on Tuesday that it met with the U.S. Food and Drug Administration (FDA) but did not come to an agreement on a path forward for the design of a clinical trial in patients with late-stage chronic kidney disease not on dialysis.&nbsp;</li><li>Akebia believes regulatory alignment for such a trial would require a significantly larger number of patients than proposed. &nbsp;</li></ul>Shares of Akebia Therapeutics (AKBA) slumped 24% on Wednesday morning after the company said that it does not expect to pursue a broad label for Vafseo for the treatment of anemia in patients with late-stage chronic kidney disease not on dialysis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-provides-update-vafseo-non-dialysis-patients">said</a> on Tuesday that it met with the U.S. Food and Drug Administration (FDA) but did not come to an agreement on a path forward for the design of a clinical trial for the use of the drug in the said patient population.While the company is yet to receive the final minutes of the meeting with the FDA, Akebia believes regulatory alignment for such a trial would require a significantly larger number of patients than proposed. This, in turn, would require “meaningfully more” time and cost to complete, and the company does not plan to initiate the trial, the company said.<h2 class="st-heading-2">What Did The CEO Say?</h2>CEO John P. Butler said that the company is “disappointed” in the meeting outcome.“We believe our decision not to pursue a broad NDD-CKD label, based on our discussion with the FDA, is in the best interests of our shareholders. We were encouraged by the discussion with FDA on smaller subgroups of CKD patients where we may be able to align on a potential clinical trial design and path forward,” he added.Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. In the second quarter ended June, the company reported Vafseo net product revenue of $13.3 million after nephrologists began prescribing it in January.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AKBA">AKBA stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user expressed optimism for the stock, saying the FDA did not shut the door on the trial in its entirety.<stembedurl>https://stocktwits.com/JonahTheTrader/message/634144578</stembedurl>Another highlighted that the company’s product is already on the market, and it has good financials.<stembedurl>https://stocktwits.com/Popeye989/message/634137009</stembedurl>AKBA stock is up by 23% this year and by 37% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/purple-biotech-shares-soar-on-breakthrough-for-experimental-cancer-drug/cLGZ8OAR3wS">Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Akebia Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion

Vafseo is currently indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.

Equity

CEO John P. Butler said that the company is “disappointed” with the outcome of its meeting with the FDA on a path forward for the design of a clinical trial of Vafseo in patients with late-stage chronic kidney disease not on dialysis.

<ul class="summary-bullets"><li>Limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months, the company said.&nbsp;</li><li>BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026. &nbsp;</li></ul>BridgeBio Pharma, Inc. (BBIO) on Monday announced that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) is a rare, inherited disorder leading to progressive weakness and wasting of the arm and leg muscles, commonly later accompanied by pulmonary muscle and cardiac muscle involvement. It is caused by mutations in the FKRP gene, impairing glycosylation of alpha-dystroglycan (αDG), a protein associated with stabilizing muscle cells.<h2 class="st-heading-2">Other Trial Observations</h2>BridgeBio<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174417/0/en/BridgeBio-Reports-Positive-Phase-3-Results-for-Small-Molecule-BBP-418-in-LGMD2I-R9-FORTIFY-Study.html"> said</a> that glycosylated αDG increased by 1.8x from baseline at 3 months, whereas the placebo group showed little change. These improvements were sustained at 12 months in BBP-418-treated individuals, it further added.Furthermore, an average reduction of 82% from baseline in serum creatine kinase, a marker of muscle damage, was observed in BBP-418-treated individuals, it added.<h2 class="st-heading-2">Drug Safety</h2>BBP-418 was well-tolerated in the study with no new or unexpected safety findings observed, the company said. Overall, interim analysis data are supportive of a favorable risk-benefit profile for BBP-418, the company said.The company now intends to file a new drug application for approval of the therapy in the first half of 2026. It plans to engage with the U.S. Food and Drug Administration to discuss data from its studies later this year.<a href="https://stocktwits.com/symbol/BBIO">BBIO shares</a> traded 9% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around BBIO jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.BBIO stock has nearly doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/neumora-therapeutics-experimental-drug-demonstrates-weight-loss-in-preclinical-studies/cLG030zR3ML">Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial

BridgeBio (BBIO) now intends to file a new drug application for the therapy's approval in the first half of 2026.

Tvardi Therapeutics (TVRD) on Monday said that its TTI-101, being evaluated in idiopathic pulmonary fibrosis (IPF), showed no benefit over placebo in a mid-stage trial.The trial was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function in patients with IPF. Idiopathic Pulmonary Fibrosis is a progressive lung disease where lung tissue thickens and scars, making it difficult to breathe. However, the study did not meet its goals, and no statistically significant differences between placebo and treatment arms were observed after a preliminary review of exploratory efficacy, it said.Shares of the company plummeted 87% in Monday’s pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TVRD">TVRD stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.Tvardi said that preliminary data showed that patients’ baseline characteristics were mostly similar across treatment arms, including those who received the two doses of TTI-101 or those who received a placebo in the trial. Furthermore, lower discontinuation rates were observed in the placebo group compared to the therapy-treated arms, it added.The company also noted that patients who demonstrated changes in the lung’s Forced Vital Capacity (FVC) were 41% for the placebo, and 39% and 44% for the 400mg and 800mg TTI-101-treated arms, respectively.“In the aggregate, we did not observe a benefit of TTI-101 treatment in this IPF study. The limited data set, high variability within treatment arms, and unexpected performance of the placebo arm make it difficult to provide more definitive conclusions at this time,” CEO Imran Alibhai said.The CEO added that the company is now conducting additional analyses to understand the trial findings further. He also noted that the company is on track to report preliminary data from the mid-stage trial of TTI-101 in hepatocellular carcinoma.TVRD stock has risen about 127% this year and more than quadrupled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-commences-production-ramp-up-at-shanghai-gigafactory/ch6SiqpR3kW">Tesla Reportedly Commences Production Ramp-Up At Its Shanghai Gigafactory</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?

The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review of exploratory efficacy. 

Cidara Therapeutics, Inc. (CDTX) on Thursday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its drug CD388 for the prevention of influenza A and B in adults and adolescents who are at higher risk of disease-related complications.The new designation is in addition to the Fast Track designation granted to the drug by the agency in June 2023. CEO Jeffrey Stein said that the designations underscore the importance of the drug as a potential new non-vaccine prophylactic for seasonal influenza.“Individuals who have chronic medical conditions, advanced age, or are immune compromised may not be adequately protected by current vaccines, leaving them at higher risk for infection and complications from flu. As a long-acting prophylactic drug, CD388’s activity does not rely on an immune response, making it a potential prevention option for high-risk individuals as well as those for whom vaccines are contraindicated,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/09/3164062/0/en/Cidara-Therapeutics-Receives-U-S-FDA-Breakthrough-Therapy-Designation-for-CD388-in-Seasonal-Influenza-Prevention.html">added</a>.The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64. The company is now looking toward advancing the drug through its ongoing late-stage trial.The Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition. Benefits of the designation include eligibility for priority review and the FDA’s organizational commitment to involving senior management to guide the company on the most efficient route to approval, the company noted.Shares of the company rose 8% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1360/118;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_12_16_14_PM_png_11f3dc4644.webp" alt="CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="1360" height="118"><figcaption>CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>H.C. Wainwright analyst Sara Nik subsequently raised the firm’s price target on Cidara Therapeutics to $150 from $110 while keeping a ‘Buy’ rating on the shares. The new price target implies a potential upside of over 52% from the stock’s closing price on Wednesday.CDTX stock nearly quadrupled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-partners-with-tensor-to-deploy-hundreds-of-avs-on-its-platform/ch67uQtR3KC">Lyft Partners With Tensor To Deploy Hundreds Of AVs On Its Platform</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral

The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.

Defender Capital, a long-term shareholder of STAAR Surgical Company, on Tuesday expressed opposition to the firm’s proposed acquisition by Alcon Inc.Defender Capital owns 1.5% of STAAR’s common stock. “The proposed sale of STAAR to Alcon for $28 per share significantly undervalues the company, especially when considering the STAAR board of directors' rejection of Alcon's previous offer for $58 per share in cash only sixteen months ago,” the shareholder said.Defender Capital further <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/defender-capital-opposes-staar-surgicals-proposed-sale-to-alcon-302577240.html">added</a> that it sees no compelling reason to sell STAAR at this time, with recent optimistic projections and outlook. The shareholder also expressed disappointment at the company board, alleging that the proposed transaction is ‘ill-advised’ and does not reflect STAAR’s prospects as a standalone company.Shares of <a href="https://stocktwits.com/symbol/STAA">STAAR Surgical</a> Company traded nearly 2% lower on Tuesday. On Stocktwits, retail sentiment around STAA stock stayed within the ‘bearish’ territory while message volume remained at ‘normal’ levels.Defender Capital is not the only one to oppose the proposed acquisition. Last month, Hong Kong-headquartered investment management firm Yunqi Capital, which holds a 5.1% stake in STAAR, <a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-shareholder-yunqi-capital-opposes-proposed-merger-with-alcon/chDQFDHR32a">alleged</a> in a letter to other shareholders that it would not necessarily be opposed to a potential merger of the two companies at an appropriate price or on other appropriate terms, but opposed the deal on the terms announced in August.Before Yunqi, Broadwood Partners, L.P., and its affiliates also announced their intention to vote against the proposed acquisition. Broadwood is STAAR’s largest shareholder, owning 27.5% of the company’s outstanding common shares.STAAR is a manufacturer of phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Alcon said in early August that the companies have entered into a definitive merger agreement under which Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash. The transaction is expected to close in about six to 12 months and represents a total equity value of approximately $1.5 billion, it added.STAA stock is up 8% this year and down approximately 23% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-shares-slump-after-reports-of-fire-at-aluminum-supplier-plant/ch6PW0NR3ha">Ford Shares Slump 5% After Reports Of Fire At Aluminum Supplier Plant: Retail Dismisses The Dip As ‘Short-Lived’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor's Note: The story has been updated to reflect Broadwood Partners' accurate stake in STAAR Surgical Company.

STAAR Surgical’s Long-Term Shareholder Says Proposed Deal With Alcon Undervalues The Company

Defender Capital, which owns 1.5% of STAAR’s common stock, highlighted STAAR’s board of directors' rejection of Alcon's previous offer of $58 per share in cash.

Lexeo Therapeutics (LXEO) announced on Tuesday that the company is considering a smaller pivotal study for LX2006 in the treatment of Friedreich's ataxia (FA) cardiomyopathy, scheduled to begin in the first half of 2026, pending finalization of the study protocol.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-progress-fda-discussions">data</a> from the planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy, the company stated after discussions with the agency.Lexeo will submit enhanced manufacturing comparability data and meet an additional nonclinical requirement before the initiation of the planned pivotal study to enable pooling, the company added.Lexeo is continuing to engage with the agency regarding the protocol of the pivotal study, it stated, adding that it believes this regulatory feedback has the potential to reduce the size and duration of the planned pivotal study. The company is also optimistic that the feedback may accelerate the overall timeline to an application submission.Updated interim clinical data from both ongoing Phase I/II studies of LX2006 show sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of Friedreich’s ataxia, the company said.FA cardiomyopathy is the leading cause of death in individuals with Friedreich’s ataxia (FA), a rare, inherited neurodegenerative disorder causing progressive damage to the nervous system, leading to impaired balance, muscle coordination, and sensory loss, often beginning in childhood. It is estimated to affect approximately 5,000 people in the U.S.Shares of the company rallied 24% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LXEO">LXEO stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1368/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_9_19_18_AM_png_3d23b7c692.webp" alt="LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1368" height="120"><figcaption>LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>LXEO stock has risen 22% this year and but fallen by approximately 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-reportedly-slashes-workforce-at-its-us-wegovy-manufacturing-plant/ch6PBqJR3WD">Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process

The company stated that data from a planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy. 

H.C. Wainwright raised its price target on AnaptysBio (ANAB) to $59 from $38 on Tuesday, following the company's announcement of its plan to split its business into two.The analyst kept a ‘Buy’ rating on the shares. The new price target implies a potential upside of about 154% to the stock’s closing price on Monday.AnaptysBio <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-intent-separate-biopharma-operations">stated </a>on Tuesday that its board of directors approved plans to explore separating its business into two independent, publicly traded companies. Upon completion of the split, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and Imsidolimab with Vanda, with a focus on protecting and returning their value, the company said.The royalty management company is expected to require minimal infrastructure and staff, and will operate under a new name, it added.Meanwhile, the other company, referred to as Biopharma Co., will focus on biopharmaceutical operations, including the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, such as Rosnilimab, ANB033, and ANB101. After the split, Biopharma Co. will launch with adequate capital to fund operations for at least two years and will also operate under a new name, the company stated.The separation is expected to be completed by the end of 2026. Anaptys CEO Daniel Faga is expected to continue as CEO of the biopharma company.Shares of the company traded 30% higher on Tuesday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANAB">ANAB stock</a> rose from ‘bullish’ to ‘extremely bullish territory’ over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_12_21_38_PM_png_239792a64d.webp" alt="ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they now expect the stock to crater.<stembedurl>https://stocktwits.com/CommercialREbroker/message/630482537</stembedurl>ANAB stock has more than doubled this year but dropped nearly 10% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-amends-deal-with-sanofi-broadens-partnership/chDDB6dR3BH">Novavax Amends Deal With Sanofi, Broadens Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level

H.C. Wainwright’s new price target of $59 implies a potential upside of about 154% to the stock’s closing price on Monday. 

MBX Biosciences, Inc. (MBX) said on Monday that its once-weekly Canvuparatide achieved the primary endpoint with statistical significance at week 12 in its mid-stage trial in adult patients with chronic hypoparathyroidism.Hypoparathyroidism is a rare endocrine disease caused by a deficiency of parathyroid hormone (PTH) released by the parathyroid glands that results in decreased calcium levels in the blood. According to MBX, the disease affects more than 250,000 individuals in the U.S. and Europe.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-announces-once-weekly-canvuparatide-achieved">noted</a> that 63% of Canvuparatide-treated patients in the study maintained serum calcium levels within the normal range and were independent of conventional therapy, including active vitamin D and calcium supplements, at week 12, with zero contribution from rescue therapy, compared to 31% in placebo-treated patients, the company stated.In the open-label extension of the trial, 79% of patients who received treatment achieved these milestones at six months. The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.Shares of the company soared 144% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MBX">MBX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Guggenheim subsequently raised its price target on MBX to $84 from $44 while keeping a ‘Buy’ rating on the shares. The results achieved the firm's "bull case," noted the analyst, who increased the firm's view of the odds of success for Canvuparatide to 75% from 50% previously. Guggenheim also argued that the data provides "clear line of sight to blockbuster-plus potential."CEO Kent Hawryluk said that the company is pleased with the results. “We believe the totality of the data support a once-weekly product profile with continuous infusion-like PTH exposure. These 12-week and 6-month results represent the potential for a meaningful improvement over current treatment options for HP patients and provide a strong foundation for further development,” he said.All doses of Canvuparatide were generally well-tolerated with no discontinuations related to the drug, and no treatment-related serious adverse events or discontinuations were recorded during the 12-week trial, the company said.MBX stock is down 46% this year and approximately 55% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-shareholder-yunqi-capital-opposes-proposed-merger-with-alcon/chDQFDHR32a">STAAR Surgical’s Shareholder Yunqi Capital Opposes Proposed Merger With Alcon – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Study

The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.

Krispy Kreme (DNUT) shares jumped over 6% before the bell on Thursday and witnessed a 633% increase in retail user message count on Stocktwits in the last 24 hours after FBI Director Kash Patel reportedly noted the company has a “good investment” opportunity.According to Bloomberg News, during his testimony in Congress, Patel was asked about his purchase of individual stocks while in office. The report added that Patel explained he has “long liked” to trade stocks.Patel noted that he saw “good investment” opportunities in Krispy Kreme and ON Semiconductor Corp. (ON), according to the report. “I just follow certain industries,” he said at the hearing, “and I thought they would be a good investment.”A user on Stocktwits noted that it was “crazy” that a Senate oversight meeting led to a boost in stock price for a donut company.<a href="https://stocktwits.com/Werewolfoflondon/message/629073308">https://stocktwits.com/Werewolfoflondon/message/629073308</a>Retail sentiment on <a href="https://stocktwits.com/symbol/DNUT">Krispy Kreme</a> jumped to ‘bullish’ from ‘bearish’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:795/97;" src="https://news.stocktwits-cdn.com/DNUT_sentiment_png_f84903838d.webp" alt="DNUT sentiment.png" width="795" height="97"><figcaption>DNUT sentiment and message volume September 18, 2025, as of 7 am ET | Source: Stocktwits</figcaption></figure>In July, Patel&nbsp;had&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://static.notus.org/3b/61/46d6712d4aff9412d01276fbf797/kashyap-patel-07-21-2025-278t.pdf">disclosed</a> that he had purchased between $15,000 and $50,000 worth of Krispy Kreme shares and between $50,000 and $100,000 worth of ON Semiconductor shares.Bloomberg noted that Joe Neguse of Colorado directed the question to Patel in the context of a growing bipartisan initiative aimed at prohibiting members of Congress from trading individual stocks.The report said that the proposed measure is part of a broader campaign to strengthen anti-corruption safeguards and that, notably, officials in the executive branch, such as Patel, would remain exempt from the restrictions under the current proposal.Shares of Krispy Kreme have declined 68% this year and lost 74% of its value in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nike-shares-are-rising-premarket-heres-why/chDcAX9R3Gt">Nike Shares Are Rising Premarket: Here's Why</a>

The Krispy Kreme corporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Krispy Kreme Stock Pops After FBI Director Kash Patel Reportedly Endorses It As A ‘Good Investment’: Retail Chatter Soars Over 600%

According to a Bloomberg News report, Patel noted during his testimony in Congress that he saw “good investment” opportunities in Krispy Kreme and ON Semiconductor Corp.

Wolfpack Research announced on Thursday its short position in EV maker Faraday Future (FFAI) and opined that it would likely revert to being a penny stock before eventually delisting.The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wolfpackresearch.com/items/ffai%3A-this-house-of-cards-is-falling-apart-as-yt-jia%E2%80%99s-latest-pump-is-built-on-fake-orders-and-a-tsunami-of-lies">stated</a> that it believes the latest pump in stock value was based on “fake orders, a rebadged Chinese minivan and a tsunami of lies” intended to induce retail investors to buy ahead of dilution.FFAI’s stock jumped on July 22 after Nature’s Miracle announced a preorder of 1000 EV minivans in a deal worth up to $100 million. However, Wolfpack thinks this is fake, provided that Nature’s Miracle does not have the cash to make such a purchase. Further, the founder of Nature’s Miracle and Faraday Future CEO Jia Yueting were classmates in business school, the firm noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/FFAI">FFAI stock</a> remained within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Wolfpack alleged, citing former employees and media reports, that the EV minivan called the FX Super One is a rebadged vehicle from Chinese automaker Great Wall Motors. The over 10,000 pre-orders for the vehicle are all non-binding, including the one made by Nature’s Miracle, it added.While the company recently announced $82 million of new financing, Faraday didn't reveal the financier, and Wolfpack believes this may be a reiteration of prior financing rounds where the CEO and other insiders appear to have used fronts to disguise that they were the ultimate source of funding. The firm also raised doubts about how the CEO has money to fund the company after emerging from his personal bankruptcy. “We think he hid assets from the bankruptcy court,” it said, while adding that this includes homes on the California coast and shares of Lucid.The ultimate goal of these moves by the company appears to be to pump up the stock ahead of massive dilution, Wolfpack alleged. FFAI is slated to vote on September 19 to increase the authorized common share count by 39% and issue shares to certain convertible note and warrant holders.YT Jia returned as co-CEO of the EV maker in April earlier this year after stepping down in 2019. However, Wolfpack believes this was “theater” since he was running the company even while he was not in the CEO position.FFAI stock is down 29% this year and approximately 57% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-supplier-magna-international-appoints-former-timken-executive-as-cfo/chwNkSJRdvj">Ford Supplier Magna International Appoints Former Timken Executive As CFO</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Faraday Future logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wolfpack Research Reveals Short Position In EV Maker Faraday Future

The firm stated that it believes the latest pump in stock value was based on “fake orders, a rebadged Chinese minivan and a tsunami of lies” intended to induce retail investors to buy. 

ProShares Trust - ProShares Ultra Russell 2000 2X Shares

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

UWM
ProShares Ultra Russell2000

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest UWM News

UWMProShares Ultra Russell2000